Real-world characteristics and treatment pattern of patients with newly diagnosed endometrial cancer in China.

Authors

null

Aijun Yin

Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China

Aijun Yin , Dong Wang , Yanlin Luo , Ruifang An , Shuzhong Yao , Yufei Shen , Li Sun , Cuirong Lei , Yan Tian , Li Wang , Dan Zhong , Manman Xu , Yuanyuan Jiang , Min Zhang , Binqi Zhang , Huirong Mao , Fengshi Dong , Yu Zhang , Beihua Kong

Organizations

Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China, Gynecological Oncology Center, Chongqing University Cancer Hospital, Chongqing, China, Department of Gynecologic Oncology, Affiliated Cancer Hospital of Zhengzhou University (Henan Cancer Hospital), Zhengzhou, China, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China, Department of Obstetrics and Gynecology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Nanjing Maternity and Child Health Hospital, Nanjing, China, Department of Gynecological Oncology, Qingdao Central Hospital, The Second Affiliated Hospital of Medical College of Qingdao University, Qingdao, China, Department of Gynecology, Xiangya Hospital Central South University, Changsha, China, Department of Gynecology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China, Qingdao Central Hospital, The Second Affiliated Hospital of Medical College of Qingdao University, Qingdao, China, MRL Global Medical Affairs, MSD China, Shanghai, China, Department of Gynecology, Xiangya Hospital, Central South University, Changsha, China, Qilu Hospital of Shandong University, Jinan, China

Research Funding

Pharmaceutical/Biotech Company
MSD China

Background: Endometrial cancer (EC) is the second most common gynecologic cancer in China with an increasing incidence. Currently, there is no comprehensive profile of EC patients in China. This real-world multicenter retrospective study aimed to depict the characteristics and treatment patterns in newly diagnosed EC patients in China. Methods: Medical records of newly diagnosed EC at 8 hospitals between January 1, 2015 and December 31, 2019 were retrospectively reviewed. The demographic and clinical characteristics at diagnosis as well as the treatment received within 6 months after diagnosis were collected. Results: A total of 1397 patients were enrolled in the study. The average age was 53.5 years. The number of patients (n=1256) classified as stage I, II, III, and IV was 885 (70.5%), 141 (11.2%), 207 (16.5%) and 23 (1.8%), respectively. The number of patients (n=1340) presented with low-grade (G1-2) and high-grade (G3) tumors was 924 (74.0%) and 324 (26.0%), respectively. Invasion of lymphovascular space was detected in 237 (17.0%) out of 1397 patients. Among 1389 patients with pathological data, pure endometrioid carcinoma (90.3%) and serous carcinoma (5.1%) accounted for the majority of pathological types. Estrogen receptor (ER) expression was positive in 91.0% (977/1074) of patients and progesterone-receptor (PR) expression was positive in 85.2% (904/1061) of patients. Mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) was identified in 26.6% (107/402) of patients. Among 1393 patients with treatment information, surgery was performed in 99.6% of patients and 66.9% received adjuvant treatment following surgery according to clinicopathological risk factors. The percentage of patients receiving adjuvant chemotherapy, adjuvant radiotherapy, and adjuvant chemoradiotherapy was 36.7%, 7.3%, and 22.0%, respectively. Among 306 patients who received chemoradiotherapy, 47.1% underwent concurrent chemoradiotherapy, 31.0% underwent sandwich chemoradiotherapy, and 21.9% underwent sequential chemoradiotherapy. Conclusions: To date, this is the first real-world study with largest sample size of EC patients in China. EC is frequently diagnosed at early 50s in Chinese patients, which is at a younger age compared with European and American population. Newly diagnosed EC patients in China are primarily treated with surgery. Chemotherapy and radiotherapy remain the main adjuvant treatment after surgery. MSI-H/dMMR patients accounted for about 1/4 of newly diagnosed patients, for whom immunotherapy may open up better prognosis in the future.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Publication Only: Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Uterine Cancer

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr e17613)

DOI

10.1200/JCO.2023.41.16_suppl.e17613

Abstract #

e17613

Abstract Disclosures

Similar Abstracts

First Author: Ting-Chang Chang

First Author: Mugdha Gokhale